Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines
Primary Purpose
Influenza, Orthomyxovirus Infections, Myxovirus Infection
Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Inactivated, split-virion, influenza vaccine
Inactivated, split-virion, influenza vaccine
Inactivated, split-virion influenza vaccine
Inactivated, split-virion influenza vaccine
Sponsored by

About this trial
This is an interventional prevention trial for Influenza focused on measuring Influenza, Orthomyxoviruses, Myxovirus Infection, Inactivated Split-virion influenza vaccine, Adults, Elderly
Eligibility Criteria
Inclusion Criteria :
- Aged 18 to 40 years (adults) or 60 to 85 years (elderly)
- Provision of a signed informed consent
- Able to attend all scheduled visits and comply with all trial procedures
- For a woman of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until 4 weeks after vaccination
- Entitlement to national social security.
Exclusion Criteria :
- For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test
- Breast-feeding woman
- Participation in another clinical trial investigating a vaccine, drug, medical device or a medical procedure in the 4 weeks preceding the trial vaccination
- Planned participation in another clinical trial during the present trial period
- Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
- Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances
- Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator
- Current alcohol abuse or drug addiction, which may interfere with the subject's ability to comply with trial procedures
- Receipt of blood or blood-derived products in the past 3 months, which might interfere with the assessment of immune response
- Receipt of any vaccine in the 4 weeks preceding the trial vaccination
- Planned receipt of any vaccine in the 4 weeks following the trial vaccination
- Known Human Immunodeficiency Virus, Hepatitis B or Hepatitis C seropositivity
- Previous vaccination against Influenza in the previous 6 months
- Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding the inclusion contraindicating IM vaccination
- Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
- Febrile illness (oral temperature >=37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Experimental
Arm Label
Study Group 1
Study Group 2
Study Group 3
Study Group 4
Arm Description
Adult, age 18 to 40 years
Adult, age 18 to 40 years
Elderly, age 60 to 85 years
Elderly, age 60 to 85 years
Outcomes
Primary Outcome Measures
To provide information concerning immune response to an inactivated, split-virion, influenza vaccine.
To provide information concerning the safety of inactivated, split-virion, influenza vaccine.
Secondary Outcome Measures
Full Information
NCT ID
NCT00776438
First Posted
October 17, 2008
Last Updated
June 16, 2015
Sponsor
Sanofi Pasteur, a Sanofi Company
1. Study Identification
Unique Protocol Identification Number
NCT00776438
Brief Title
Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines
Official Title
Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated Either With an Inactivated Influenza Vaccine Administered Via the Intradermal Route or an Inactivated Influenza Vaccine Administered Via the Intramuscular Route
Study Type
Interventional
2. Study Status
Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
February 2009 (Actual)
Study Completion Date
April 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi Pasteur, a Sanofi Company
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To further characterize the immune responses induced after an influenza vaccination performed either via the ID or the IM routes in two clearly distinct populations.
Objectives:
To describe the immune response per age group and vaccine group after vaccination.
To describe the safety of the vaccines per age group and per vaccine group after vaccination.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza, Orthomyxovirus Infections, Myxovirus Infection
Keywords
Influenza, Orthomyxoviruses, Myxovirus Infection, Inactivated Split-virion influenza vaccine, Adults, Elderly
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
160 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Study Group 1
Arm Type
Experimental
Arm Description
Adult, age 18 to 40 years
Arm Title
Study Group 2
Arm Type
Experimental
Arm Description
Adult, age 18 to 40 years
Arm Title
Study Group 3
Arm Type
Experimental
Arm Description
Elderly, age 60 to 85 years
Arm Title
Study Group 4
Arm Type
Experimental
Arm Description
Elderly, age 60 to 85 years
Intervention Type
Biological
Intervention Name(s)
Inactivated, split-virion, influenza vaccine
Intervention Description
0.1 mL, Intradermal
Intervention Type
Biological
Intervention Name(s)
Inactivated, split-virion, influenza vaccine
Other Intervention Name(s)
Vaxigrip®
Intervention Description
0.5 mL, Intramuscular
Intervention Type
Biological
Intervention Name(s)
Inactivated, split-virion influenza vaccine
Intervention Description
0.1 mL, Intradermal
Intervention Type
Biological
Intervention Name(s)
Inactivated, split-virion influenza vaccine
Other Intervention Name(s)
Vaxigrip®
Intervention Description
0.5 mL, Intramuscular
Primary Outcome Measure Information:
Title
To provide information concerning immune response to an inactivated, split-virion, influenza vaccine.
Time Frame
21 days post-vaccination
Title
To provide information concerning the safety of inactivated, split-virion, influenza vaccine.
Time Frame
21 days post-vaccination and entire study duration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria :
Aged 18 to 40 years (adults) or 60 to 85 years (elderly)
Provision of a signed informed consent
Able to attend all scheduled visits and comply with all trial procedures
For a woman of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until 4 weeks after vaccination
Entitlement to national social security.
Exclusion Criteria :
For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test
Breast-feeding woman
Participation in another clinical trial investigating a vaccine, drug, medical device or a medical procedure in the 4 weeks preceding the trial vaccination
Planned participation in another clinical trial during the present trial period
Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances
Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator
Current alcohol abuse or drug addiction, which may interfere with the subject's ability to comply with trial procedures
Receipt of blood or blood-derived products in the past 3 months, which might interfere with the assessment of immune response
Receipt of any vaccine in the 4 weeks preceding the trial vaccination
Planned receipt of any vaccine in the 4 weeks following the trial vaccination
Known Human Immunodeficiency Virus, Hepatitis B or Hepatitis C seropositivity
Previous vaccination against Influenza in the previous 6 months
Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding the inclusion contraindicating IM vaccination
Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
Febrile illness (oral temperature >=37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Sanofi Pasteur Inc
Official's Role
Study Director
Facility Information:
City
Lyon Sud
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
25483667
Citation
Nougarede N, Bisceglia H, Rozieres A, Goujon C, Boudet F, Laurent P, Vanbervliet B, Rodet K, Hennino A, Nicolas JF. Nine mug intradermal influenza vaccine and 15 mug intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults. Hum Vaccin Immunother. 2014;10(9):2713-20. doi: 10.4161/hv.29695.
Results Reference
result
Links:
URL
http://www.sanofipasteur.com
Description
Related Info
Learn more about this trial
Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines
We'll reach out to this number within 24 hrs